{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T14:05:57Z","timestamp":1785333957172,"version":"3.55.0"},"reference-count":5,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T00:00:00Z","timestamp":1689897600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11,16]]},"abstract":"<jats:p>We reported\u00a0the case of a patient with Netherton syndrome (NS) who showed remarkable cutaneous improvement using upadacitinib in the short term, but the efficacy decreased long term. This patient\u2019s case demonstrates that Janus kinase inhibitors have reduced long-term clinical efficacy, which is the same as other biologic therapies used to treat patients with NS. This shows that NS is a complex skin disorder and more studies and clinical trials are required focusing on the long-term efficacy of these drugs.<\/jats:p>","DOI":"10.1093\/ced\/llad242","type":"journal-article","created":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T13:23:29Z","timestamp":1689945809000},"page":"1379-1381","source":"Crossref","is-referenced-by-count":13,"title":["Treatment of Netherton syndrome with upadacitinib"],"prefix":"10.1093","volume":"48","author":[{"given":"Xinyu","family":"Li","sequence":"first","affiliation":[{"name":"Department of Dermatology and Venereology, 1st Hospital of Jilin University , Changchun city, Jilin Province , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5228-977X","authenticated-orcid":false,"given":"Bing","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, 1st Hospital of Jilin University , Changchun city, Jilin Province , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, 1st Hospital of Jilin University , Changchun city, Jilin Province , China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,7,21]]},"reference":[{"key":"2023111605085206800_llad242-B1","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1159\/000525987","article-title":"Treatment experiences with intravenous immunoglobulins, ixekizumab, dupilumab, and anakinra in Netherton syndrome: a case series","volume":"239","author":"Ragamin","year":"2023","journal-title":"Dermatology"},{"key":"2023111605085206800_llad242-B2","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1068260","article-title":"JAK-STAT signaling pathway in the pathogenesis of atopic dermatitis: an updated review","volume":"13","author":"Huang","year":"2022","journal-title":"Front Immunol"},{"key":"2023111605085206800_llad242-B3","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/j.jaci.2021.08.024","article-title":"Netherton syndrome subtypes share IL-17\/IL-36 signature with distinct IFN-\u03b1 and allergic responses","volume":"149","author":"Barbieux","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"2023111605085206800_llad242-B4","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14051001","article-title":"A comprehensive overview of globally approved JAK inhibitors","volume":"14","author":"Shawky","year":"2022","journal-title":"Pharmaceutics"},{"key":"2023111605085206800_llad242-B5","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1001\/jamadermatol.2023.0561","article-title":"Treatment of Netherton syndrome with abrocitinib","volume":"159","author":"Zheng","year":"2023","journal-title":"JAMA Dermatol"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llad242\/51859426\/llad242.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/48\/12\/1379\/53456444\/llad242.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/48\/12\/1379\/53456444\/llad242.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T05:09:42Z","timestamp":1700111382000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/48\/12\/1379\/7227530"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,21]]},"references-count":5,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,7,21]]},"published-print":{"date-parts":[[2023,11,16]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llad242","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,12]]},"published":{"date-parts":[[2023,7,21]]}}}